All In Biotech

Drug Trial Radar · NCT03959488

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

A Phase 2/3 Randomized, Double-blind, Palivizumab-controlled Study to Evaluate the Safety of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in High-risk Children (MEDLEY)

Last checked: Nov 20, 2026Latest source record: Sep 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 925 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

925

Actual

Start

Jul 30, 2019

Primary completion

May 3, 2021

Study completion Jan 20, 2023

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 1 year
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety and tolerability of MEDI8897 compared to palivizumab when administered to preterm infants entering their first RSV season and children with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and second RSV season.

Conditions

  • Respiratory Syncytial Virus Infections

Interventions

  • MEDI8897Drug

    Anti-RSV monoclonal antibody with an extended half-life

  • PalivizumabDrug

    Approved anti-RSV monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety and Tolerability of MEDI8897 as Assessed by the Occurrence of All Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) and Adverse Events of Special Interest (AESIs) and New Onset Chronic Disease (NOCD)Time frame: 360 days post first dose

Locations

128 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Anaheim, California

  • Research Site

    Long Beach, California

  • Research Site

    Los Angeles, California

  • Research Site

    National City, California

  • Research Site

    Paramount, California

  • Research Site

    West Covina, California

  • Research Site

    Aurora, Colorado

  • Research Site

    Colorado Springs, Colorado

  • Research Site

    Washington D.C., District of Columbia

  • Research Site

    Atlanta, Georgia

  • Research Site

    Chicago, Illinois

  • Research Site

    Indianapolis, Indiana

  • Research Site

    South Bend, Indiana

  • Research Site

    West Des Moines, Iowa

  • Research Site

    Louisville, Kentucky

  • Research Site

    Jackson, Mississippi

  • Research Site

    Columbia, Missouri

  • Research Site

    Mineola, New York

  • Research Site

    Syracuse, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Greenville, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Columbus, Ohio

  • Research Site

    Greenville, South Carolina

  • Research Site

    Corpus Christi, Texas

  • Research Site

    Layton, Utah

  • Research Site

    St. George, Utah

  • Research Site

    Charlottesville, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Morgantown, West Virginia

  • Research Site

    Graz, Austria

  • Research Site

    Brussels, Belgium

  • Research Site

    Ghent, Belgium

  • Research Site

    Montana, Bulgaria

  • Research Site

    Pazardzhik, Bulgaria

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Rousse, Bulgaria

  • Research Site

    Sliven, Bulgaria

Showing 40 of 128 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.